Premium
Oncolytic viral therapy for pancreatic cancer
Author(s) -
Rahal Ahmad,
Musher Benjamin
Publication year - 2017
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.24626
Subject(s) - oncolytic virus , medicine , immunotherapy , pancreatic cancer , clinical trial , cancer , oncology , tumor microenvironment , chemotherapy , viral therapy , adenocarcinoma , immunology , covid-19 , disease , infectious disease (medical specialty)
Outcomes of pancreatic adenocarcinoma (PDA) remain dismal despite extensive clinical investigation. Combination chemotherapy provides modest improvements in survival above best supportive care, and immunotherapy has thus far not proven effective. Nevertheless, growing insight into antitumor immunity and the tumor microenvironment has inspired the discovery of novel agents targeting PDA. Oncolytic viruses represent an emerging class of immunotherapeutic agents that have undergone extensive preclinical investigation and warrant further investigation in well‐designed clinical trials.